Skip to main content
  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
      • Research Guidelines
        • Minimum Information About Microarray Data Experiments (MIAME)
      • Abstract
      • Acknowledgments
      • Clinical Implications (Only by invitation)
      • Conflict(s) of Interest/Disclosure(s) Statement
      • Figure Legends
      • Figures
      • Novelty and Significance: 1) What Is New, 2) What Is Relevant?
      • References
      • Sources of Funding
      • Tables
      • Text
      • Title Page
      • Online/Data Supplement
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
      • Change of Authorship Form
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
  • Facebook
  • Twitter

  • My alerts
  • Sign In
  • Join

  • Advanced search

Header Publisher Menu

  • American Heart Association
  • Science Volunteer
  • Warning Signs
  • Advanced Search
  • Donate

Hypertension

  • My alerts
  • Sign In
  • Join

  • Facebook
  • Twitter
  • Home
  • About this Journal
    • General Statistics
    • Editorial Board
    • Editors
    • Information for Advertisers
    • Author Reprints
    • Commercial Reprints
    • Customer Service and Ordering Information
  • All Issues
  • Subjects
    • All Subjects
    • Arrhythmia and Electrophysiology
    • Basic, Translational, and Clinical Research
    • Critical Care and Resuscitation
    • Epidemiology, Lifestyle, and Prevention
    • Genetics
    • Heart Failure and Cardiac Disease
    • Hypertension
    • Imaging and Diagnostic Testing
    • Intervention, Surgery, Transplantation
    • Quality and Outcomes
    • Stroke
    • Vascular Disease
  • Browse Features
    • AHA Guidelines and Statements
    • Acknowledgment of Reviewers
    • Clinical Implications
    • Clinical-Pathological Conferences
    • Controversies in Hypertension
    • Editors' Picks
    • Guidelines Debate
    • Meeting Abstracts
    • Recent Advances in Hypertension
    • SPRINT Trial: the Conversation Continues
  • Resources
    • Instructions to Reviewers
    • Instructions for Authors
    • →Article Types
    • → Submission Guidelines
    • →Tips for Easier Manuscript Submission
    • → General Instructions for Revised Manuscripts
    • → Costs to Authors
    • → Open Access, Repositories, & Author Rights Q&A
    • Permissions to Reprint Figures and Tables
    • Journal Policies
    • Scientific Councils
    • AHA Journals RSS Feeds
    • International Users
    • AHA Newsroom
  • AHA Journals
    • AHA Journals Home
    • Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
    • Circulation
    • → Circ: Arrhythmia and Electrophysiology
    • → Circ: Genomic and Precision Medicine
    • → Circ: Cardiovascular Imaging
    • → Circ: Cardiovascular Interventions
    • → Circ: Cardiovascular Quality & Outcomes
    • → Circ: Heart Failure
    • Circulation Research
    • Hypertension
    • Stroke
    • Journal of the American Heart Association
Brief Review

Y Are Males So Difficult to Understand?

A Case Where “X” Does Not Mark the Spot

Amanda K. Sampson, Garry L.R. Jennings, Jaye P.F. Chin-Dusting
Download PDF
https://doi.org/10.1161/HYPERTENSIONAHA.111.187880
Hypertension. 2012;59:525-531
Originally published February 15, 2012
Amanda K. Sampson
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Garry L.R. Jennings
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jaye P.F. Chin-Dusting
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Tables
  • Info & Metrics
  • eLetters

Jump to

  • Article
    • Introduction
    • Sources of Funding
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters
Loading

Introduction

Cardiovascular disease (CVD) remains one of the leading causes of death and disability in the Western world, accounting for 48 500 deaths and one third of all mortality in Australia in 2008.1 From 45 to 64 years of age there are significant sex differences in the mortality rates from CVD, with deaths rates in men ≈3 times that of age-matched women.2 Hypertension is the leading risk factor for the development of CVD, with men showing a higher arterial pressure than women during the ages of 20 to 65 years.3 Up until menopause, there are significant sex differences in blood pressure, vascular reactivity, and renal function.4–11 Not only are the rates of mortality sexually dimorphic but so are the symptoms experienced and disease development,4,12 resulting in a poorer outcome in men than in women. The response to treatment also differs between the sexes. For example, hypertensive women treated with an angiotensin receptor blocker have a better survival rate than women treated with an angiotensin-converting enzyme (ACE) inhibitor, whereas there is no difference in response to either agent in hypertensive men (as seen by the hazard ratio for treatment with an angiotensin receptor blocker versus treatment with ACE inhibitor of 0.69 in women and 1.10 in men).13–16 These data suggest that there are sex differences in the mechanisms underlying the development of hypertension. Despite these sex differences, the exact mechanism(s) underlying the increased morbidity and mortality in men remains elusive. Previous human studies have reported significant associations between the Y chromosome and blood pressure in Australian, Polish, and Scottish populations, suggesting that the Y chromosome may play a role17,18; however, this was not the case in a Spanish cohort.19 Further evidence from population studies suggests that the blood pressure status in men is largely determined by the paternal and not maternal blood pressure status,20 supporting the hypothesized influence of the Y chromosome. What is increasingly clear is that further investigations are required to determine the mechanisms underlying sex differences in blood pressure regulation. This review describes 2 novel animal models developed to investigate the role of the sex chromosomes in blood pressure regulation and new knowledge of the role of the Y chromosome in arterial pressure regulation, which has been provided by these models.

Why is the cardiovascular profile of men so different from that of women and so poorly understood? Physiologically speaking, the 2 key differences between males and females are the levels of the sex hormones (estrogen and testosterone) and the sex chromosome complement (XX or XY). As with all complex physiological research questions, the ability to design experiments that alter only 1 parameter of the sex axis has been particularly challenging, and each experimental model involves multiple complex interactions requiring careful consideration. Despite these challenges, significant advances in the knowledge of sex differences, specifically the role of the sex hormones and the sex chromosome complement, have now occurred, enabling us to understand the contribution of each of these components.

Historically, much of our understanding of the mechanisms underlying sex differences originates from studies investigating the role of the sex hormones, where animals were gonadectomized and hormone replaced. This approach provided clear evidence demonstrating the role of estrogen and testosterone in blood pressure regulation and the cardiovascular system. Of course, the role of the sex hormones is not always the same across species. For example, neither estrogen withdrawal (via ovariectomy) nor replacement changes arterial pressure in the spontaneously hypertensive rat (SHR).21 (For a detailed discussion of the mechanisms underlying estrogen effects on the cardiovascular system, see recent reviews by Xing et al22 and Yang and Reckelhoff.23)

Testosterone Can Stimulate Both Vasodilatory and Vasoconstrictory Pathways

The evidence of decreased arterial pressure in castrated SHRs, Dahl salt-sensitive, and Goldblatt hypertensive males compared with intact males suggests that testosterone influences arterial pressure regulation in diseased states.24–31 Furthermore, elegant studies by Reckelhoff et al30 demonstrated that testosterone treatment of ovariectomized female SHRs results in increased arterial pressure, suggesting that testosterone is a prohypertensive stimulus.

Interestingly, testosterone can stimulate both vasodilatory and vasoconstrictory pathways. In terms of vascular tone, testosterone causes an increase in sympathetic nervous system activity via an increase in tyrosine hydroxylase (leading to an increase in circulating noradrenaline levels)32,33 and an increased release of 2 potent vasoconstrictors, angiotensin II (via upregulation of angiotensinogen production and renin activity34–37) and neuropeptide Y.38 Studies have demonstrated that the acute effects of testosterone are largely vasodilatory and are not mediated by conversion to estrogen or by activation of the androgen receptor.39 It is interesting to note that the gene encoding the androgen receptor is located on the X chromosome.40 It is suggested that testosterone-induced vasodilation may occur via regulation of potassium channels and not via activation of NO or regulation of calcium channels.39,41 Testosterone has also been shown to promote atherosclerosis by stimulating changes in lipid profile (increasing low-density lipoproteins and decreasing high density lipoproteins),42 as well as alterations in vascular cell adhesion molecule 1,43 therefore increasing monocyte adhesion to the vessel wall in the early stages of plaque formation.

The role of the kidney in blood pressure regulation has been elegantly highlighted using renal transplantation studies, which demonstrated that normotensive rats that received a hypertensive kidney transplant developed hypertension and hypertensive rats that received a normotensive kidney transplant exhibited decreased arterial pressure compared with hypertensive rats.44 Consistent with the human condition, male SHRs have significantly higher arterial pressure than age-matched female SHRs. Given this difference in blood pressure between male and female SHRs, similar renal transplantation studies have also been performed in hypertensive rats to examine the role of the sex hormones. Transplantation of male SHR kidneys into female SHR rats, however, does not result in increased blood pressure and the converse, transplantation of female SHR kidneys into male SHRs does not reduce blood pressure.45 These data suggests that, in the hypertensive rat, the hormonal milieu contributes to blood pressure regulation to a greater extent than the nonhormonal effects of the kidney. Extending this work, Reckelhoff et al46 further investigated the role of the androgen receptor in the pressor effects of testosterone and demonstrated that blockade of the androgen receptor significantly lowered mean arterial pressure. This evidence suggests that the pressor response to testosterone is mediated through the androgen receptor. Testosterone can also directly interact with the renin-angiotensin system (RAS), upregulating angiotensinogen production, renin activity, and angiotensin II type 1 receptor expression, thereby enhancing the vasoconstrictory arm of the RAS.34–37 In fact, plasma renin activity has been shown to be higher in males compared with females and is significantly reduced after castration in animals and enhanced in postmenopausal women.30,47 Furthermore, the increase in angiotensinogen production, renin activity, and angiotensin II results in a rightward shift of the pressure-natriuresis response in males, resulting in sodium and water retention.48,49 In addition to acting on the RAS to stimulate sodium and water retention, testosterone has been shown to upregulate the epithelial sodium channel-α, leading to enhanced sodium and water retention in the kidney,50 which further contributes to increased arterial pressure in the presence of testosterone.

However, the sex hormones do not entirely account for differences between the sexes. Epidemiological data have demonstrated that 30% to 50% of the variation in blood pressure between individuals is attributable to genetic factors.50,51 Given the differences in arterial pressure between males and females and the obvious genetic difference in the sex chromosomes between the sexes, it is suggested from both human and animal studies that the Y chromosome plays an integral role in the development of hypertension in males.17,18,52,53

Y Chromosome Can Influence Blood Pressure Regulation

The human Y chromosome is ≈58 Mb long and encodes 86 genes, which result in 23 distinct proteins.54 The role of these genes in sex organ development,55–57 testosterone production,55–57 and fertility58,59 has been determined previously in humans. However, the exact contribution of the Y chromosome in the development of hypertension remains largely unknown. What is increasingly evident is that, in terms of cardiovascular function, the Y chromosome has both nongenomic effects (via the actions of testosterone, which may be independent of genetic interactions or may indirectly influence gene expression and regulation) and direct genomic effects. These genomic effects have been highlighted by the use of highly specialized animal models, which have provided the opportunity to dissect the role of the Y chromosome as distinct from that of testosterone.

Given the fact that the Y chromosome contains a gene(s) that encodes for testes development and testosterone production, it would seem that the hormonal and genetic influences of the Y chromosome are intrinsically linked and are, therefore, difficult to investigate independently. The use of 2 novel animal models to investigate the influence of the Y chromosome and the sex hormones on CVD development has extended the previous limitations of experimental design. Both of these models aim to remove or control for the influence of hormonal status (the presence or absence of testosterone) to determine the role of the Y chromosome genes, and both have significantly advanced our understanding of the mechanisms underlying male development of CVD. These models are the four core genotype (FCG) mouse model (developed by de Vries et al60) and the Y consomic rat model (developed using the normotensive Wistar Kyoto [WKY] and the SHR strains by Ely and Turner52 and later using stroke-prone SHR [SHRSP] and WKY strains by Negrin et al53).

FCG Mouse Model

The FCG mouse model was created to address the hypothesis that the XX or XY genotype accounts for sex differences independent of the gonadal or hormonal status. This model is based on 2 key findings that the development of ovaries and production of estrogen are the default position during fetal development and occur in the absence of testosterone61 and that the Sry gene located on the Y chromosome encodes for testes development and testosterone production.62,63 The FCG model was developed by crossing 2 mouse models, one in which the Sry gene had been spontaneously deleted from the Y chromosome (named Y−) with a strain in which the Sry gene had been inserted onto an autosome (Figure 1).60 This cross results in the formation of XX and XY− with Sry on an autosome (named XXSry and XY−Sry listed as male according to gonadal phenotype, XXM and XYM), which develop testes and produce testosterone, and the formation of XX and XY− lacking the Sry gene (XX and XY− listed as female according to gonadal phenotype, XXF and XYF), which develop ovaries and produce estrogen (Figure 1).60 The offspring produced (XYM, XXM, XYF, and XXF) are then examined using a 2 by 2 comparison, which accounts for differences in hormonal status (XXM + XYM versus XXF + XYF), as well as sex chromosome complement (XXM + XXF versus XYM + XYF). The advantage of this approach is that the Y chromosome genetic complement can be assessed in the presence and absence of testosterone. This provides the opportunity to dissect the contribution of the sex chromosome complement and has yielded novel evidence of the genetic contribution to sex differences independent of hormonal status.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Four core genotypes (FCG) mouse model illustrating the progeny that result from the breeding of a female XX with a male XY−Sry, which has the Sry gene located on an autosome (A). The offspring produced are, therefore, XY− and XX females and XY−Sry and XXSry males with sex (male or female) indicative of gonadal phenotype (adapted with permission from Ji et al65).

To date, the majority of studies using the FCG model have investigated sex differences in behavior and neural function. Investigations include sex differences in aggression, parenting, social interaction, nociception, habit formation related to drug abuse, neural tube closure, multiple sclerosis, and systemic lupus erythematosus (for a comprehensive review of these investigations see Arnold et al64). These studies have significantly advanced the field of sex differences in brain function and behavior. To our knowledge, this FCG model has only recently been used to study sex differences in blood pressure regulation and CVD, with the first article published in 2010.65 Given the known sex differences in renal, cardiac, and vascular function and the pathophysiology of CVD, the FCG model has the potential to greatly advance our understanding of sex differences in blood pressure regulation and cardiovascular function.

Y Consomic Rat Model

In contrast, the Y consomic rat model approach was designed to specifically test the hypothesis that there are genes located on the Y chromosome that influence the development of CVD in the presence of testosterone. The consomic model involves the production of 2 strains of rat, one with the normotensive WKY autosomes and X chromosome in which the hypertensive SHR Y chromosome has been introgressed (WKY.SHR[Y]; Figure 2) and the other that has the hypertensive SHR autosomes and X chromosome with the normotensive WKY Y chromosome introgressed (SHR.WKY[Y]; Figure 2). The nomenclature of the consomic strains is as follows: the first abbreviation indicates the background strain (the origin of the autosomes and X chromosome), and the second abbreviation indicates the origin of the introgressed Y chromosome. Investigation of these consomic strains in parallel with their parental strains allows for the dissection of the “hypertensive” versus “normotensive” Y chromosome effects. The advantage of this approach is that all 4 of the strains are exposed to typical male cues (eg, testes development, testosterone production, and androgen receptors), suggesting that any differences observed are unlikely attributed to the effects of testosterone per se.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Y consomic rat breeding design and progeny. The top panel depicts the parental cross resulting in the generation of Wistar-Kyoto (WKY), spontaneously hypertensive rat (SHR), or the consomic cross with the WKY background strain and the Y chromosome from the SHR (WKY.SHR[Y]) or the SHR background and the Y chromosome from the WKY (SHR.WKY[Y]). The bottom panel illustrates the progeny that result from this breeding approach.

Limitations of the FCG Mouse Model and the Y Consomic Rat Model

As with all animal models, both have some limitations. The FCG model has 4 main restrictions. First, the FCG model can be used to determine the contribution of the sex chromosome complement but is unable to distinguish between the influence of the X chromosome compared with the Y chromosome. Second, the Sry gene has been shown recently to have functions independent of testes development and testosterone production,66 which are difficult to dissect in the FCG model and complicate the interpretation of the experimental findings in this model. Third, the FCG model assumes that the genes located on the Y chromosome will have the same expression, regulation, and function in the absence of typical male cues (testes development, testosterone production, and androgen receptors) and/or the presence of female cues (ovary development and estrogen production). Last, the FCG model assumes that introgression of the Sry locus onto an autosome (as opposed to the original location on the Y chromosome) will not alter its activity and/or expression.

In contrast, the Y consomic rat model is unable to be used to determine the contribution of the X chromosome, because this model uses males that have the same number of X chromosomes. Furthermore, the Y consomic approach does not investigate the contribution of the Y chromosome in the absence of previous or continued testosterone stimulation. That is, even after castration, the Y consomic model cannot be used to directly answer the question as to whether the genes located on the Y chromosome have in some way been influenced by the presence of testes and testosterone before castration. Despite the obvious species difference between these models, what is particularly striking is that the limitations of one represent the strengths of the other, and as such we suggest that the findings of these 2 models should be interpreted together to provide the best insights into the mechanisms underlying sex differences in males. So, what have we learned about the role of Y chromosome in CVD from these models?

The Sex Chromosome Complement Influences Blood Pressure Regulation

In contrast to the human condition, sex differences in blood pressure have only been reported in animal models of disease, such as Goldblatt hypertensive rats, SHRs, Dahl-salt sensitive rats, and angiotensin II–induced hypertension. Therefore, investigation of the FCG model in the context of angiotensin II–induced hypertension provides a model with enhanced sex differences compared with the normotensive situation. Ji et al65 used the FCG model to investigate the effect of the sex chromosomes on angiotensin II–induced hypertension. There was no difference in blood pressure before angiotensin II treatment between any of the genotypes (XXF, XYF, XXM, and XYM), which is not surprising, because all of the rats were gonadectomized before entering the study protocol. Ji et al65 reported for the first time that sex chromosome complement significantly influenced blood pressure response to chronic angiotensin II infusion, with the XY genotype (XYM and XYF) having a blunted pressor response to angiotensin II infusion compared with the XX genotype (XXM and XXF). These data are surprising given the growing body of work demonstrating in both humans and animal models that females have a blunted pressor response to angiotensin II infusion compared with males.15,67–72 It is tempting to speculate that the sex hormones and the sex chromosome complement may in fact have opposite effects and the sum of these effects may determine the net outcome, a hypothesis that will become clearer when understanding of the role of the X and Y chromosomes draws closer to, or even matches, the understanding of the sex hormones. Conversely, gonadal sex did not contribute to blood pressure responses to chronic angiotensin II infusion, but there were significant differences in heart rate depending on gonadal sex, with the female phenotype demonstrating a higher heart rate than the male phenotype.65 These data provide the first evidence that the sex chromosome complement (XX or XY) plays an important role in blood pressure regulation irrespective of gonadal sex. As mentioned previously, studies investigating the FCG model unfortunately cannot dissect the influence of the X versus Y chromosome. In this instance, the studies conducted in the Y consomic model extend the work conducted in the FCG model.

The Y Chromosome Accounts for 12 to 15 mm Hg of Systolic Blood Pressure

Ely et al52 were the first to demonstrate the influence of the Y chromosome on blood pressure regulation. Introgression of the hypertensive Y chromosome from the SHR into the WKY background strain resulted in an increase in systolic blood pressure of 12 mm Hg with the introgression of the normotensive WKY Y chromosome into the SHR, resulting in a decrease in systolic blood pressure of ≈14 mm Hg compared with the SHR.52 This finding was confirmed using a similar Y consomic approach in the SHRSP and WKY rat strains originating from the Glasgow colony.53 Negrin et al53 observed higher arterial pressure in the WKY.SPGlaY compared with the WKY (15 mm Hg higher), demonstrating that, in the WKY, arterial pressure level is influenced by the hypertensive Y chromosome. Arterial pressure responses to a high salt challenge were also shown to be Y chromosome dependent. Negrin et al53 demonstrated that, after 2 weeks of 1% salt challenge, the SP.WKYGlaY had lower systolic pressure compared with the SHRSP (30 mm Hg lower), despite the fact there was no significant difference in systolic pressure between SHRSP and SP.WKYGlaY before the salt challenge. Taken together, these data demonstrates that the Y chromosome influences arterial pressure regulation and supports the hypothesis that there may be a hypertensive Y. The intriguing Y chromosome–dependent differences in response to salt treatment are in line with recent reports demonstrating that renal overexpression of the Sry3 gene, a gene that is a member of the Sry gene family and is located exclusively on the SHR Y chromosome, resulted in a 50% increase in renal sodium reabsorption in Sry3-overexpressed WKY rats compared with control WKY rats.73 The authors suggest that this may be explained by an increase in renal angiotensin II, known to promote vasoconstriction and sodium reabsorption in the kidney.73 They also observed that overexpression of Sry3 resulted in a decrease in glomerular filtration rate, which is of particular interest given the sex differences in the rates and progression of end-stage renal disease in humans, with men progressing at a faster rate than premenopausal women.74–76

Members of the Sry Gene Family, Located on the Y Chromosome, Influence Arterial Pressure Regulation via Interaction With the Sympathetic Nervous System and the RAS

Ely and Turner et al,52 using the Y consomic rat approach, have demonstrated novel blood pressure regulation effects of the Sry gene family, independent of its role in gonad development. Turner et al66 have provided compelling evidence supporting the prohypertensive effects of the Sry gene family, which is located in the nonrecombining region of the Y chromosome. In the rat there are multiple copies of the Sry gene, which is a highly conserved gene encoding for testes development and testosterone production (as described in the FCG mouse model).

The impetus to study the influence of the Sry genes in blood pressure regulation arose from the finding that the Sry gene family members are expressed not only in sex determining organs, such as the testes, but also in tissues involved in blood pressure regulation, such as the brain, kidney, and adrenal gland.77–79 In the rat there are ≤7 copies of the Sry gene, Sry1, Sry2, Sry3, Sry3A, Sry3BI, Sry3B, and Sry3C.66 Interestingly, all of the copies are found in the hypertensive SHR strain, with only 6 copies found in the WKY strain; Sry3 is found exclusively on the SHR Y chromosome. Ely and colleagues73,80 have successfully sequenced the Sry copies and have determined, via renal overexpression studies using electroporation, that Sry1 and Sry3 elevate blood pressure by 10 to 20 mm Hg, whereas Sry2 does not influence blood pressure.73 The increase in blood pressure by Sry1 overexpression is mediated via an increase in sympathetic nervous system activity, because Sry1 directly enhances tyrosine hydroxylase promoter activity81 and thereby increases noradrenaline levels. The concept of sympathetic nervous system involvement in blood pressure regulation is far from novel.82–86 However, given the recent success of renal denervation in the treatment of essential hypertension,87,88 a genetic mechanism underlying sympathetic nervous system overstimulation can be hypothesized, at least in males.

Conversely, Sry3 can interact with the RAS in vitro to upregulate angiotensinogen, renin, and ACE promoter activity and to decrease ACE2 promoter activity, suggesting a shift in the RAS toward enhanced vasoconstrictive responses in the presence of Sry3.89 The in vivo functional consequences of Sry3 on the RAS are not yet fully elucidated; however, Ely et al73 demonstrated recently that increased expression of Sry3 in vivo, achieved by electroporation of exogenous Sry3, resulted in a 40% increase in renal ACE concentration and concomitantly increased renal angiotensin II concentration. As with the function of all genes, determining the exact influence of these Sry copies in vivo will be complex. It is likely that the activity of these genes (in this case, the interaction of the Sry genes with other gene promoters, eg, angiotensinogen) in vivo will be significantly different to the in vitro responses. For example, previous work has demonstrated that the ACE promoter contains ≥2 shear stress response elements,90 as well as 2 cyclic adenosine-monophosphate response elements,91 which also regulate promoter activity, in addition to the effects of the Sry3 gene demonstrated in vitro.73 Hence, in the in vivo setting, the possible role of Sry3 to regulate ACE promoter activity may be masked by other factors also contributing to ACE promoter activity, particularly in the SHR and SHRSP hypertensive models, where shear stress is likely to be a main contributor. Nonetheless, the RAS plays a major role in the regulation of blood pressure, with a growing body of evidence demonstrating that the mean arterial pressure pressor response to angiotensin II is attenuated in females compared with males.15,69–72,92 As discussed previously, the sex hormones are known to interact directly with the RAS49,93–95; however, the potential nonhormonal sex differences in the regulation of the RAS are less well defined. Recent work by Liu et al96 reported that male mice have a higher renal ACE2 activity than female mice, perhaps suggesting a greater influence of the newly discovered vasodilatory arm of the RAS in males. The ACE2 gene is located on the X chromosome, which opens the possibility for sex differences in the expression levels between males and females dependent on the number of X chromosomes present (1 in males and 2 in females) and the complex nature of X chromosome inactivation. Liu et al96 suggest that ACE2 activity is not sex chromosome dependent but rather estrogen dependent. Using the FCG mouse model, Liu et al96 measured ACE2 activity in kidneys from intact, gonadectomized, and gonadectomized + estrogen-replaced mice and observed that estrogen replacement reduced ACE2 activity, irrespective of sex chromosome complement.96 These data suggests that the sex chromosome complement does not influence the ACE2 expression in the FCG mouse model.96

Future Directions, Conclusions, and Perspectives

Investigation of blood pressure regulation in the FCG mouse model and the Y consomic rat model has significantly advanced the understanding of the mechanisms underlying the sex differences in blood pressure observed across all species. Despite a number of well-designed, large-scale, genomewide association studies, the exact genes involved in arterial pressure regulation remain difficult to determine, much less the influence of these genes in the complex sex differences in blood pressure regulation. The promising findings using the FCG and Y consomic animal models provide compelling evidence of the contribution of the sex chromosome complement, in particular the Y chromosome in blood pressure regulation. By using these novel animal models to investigate the sex differences in blood pressure regulation and CVD, researchers are afforded the opportunity to elucidate the mechanisms underlying these sex differences that are observed across species and apply the findings to the study of human biology.

Sources of Funding

This work is supported by a program grant from the National Health and Medical Research Council of Australia and in part by the Victorian Government Occupational Infrastructure Support Program.

Disclosures

None.

Footnotes

  • This paper was sent to John E. Hall, consulting editor, for review by expert referees, editorial decision, and final disposition.

  • Received November 15, 2011.
  • Revision received December 4, 2011.
  • Accepted January 6, 2012.
  • © 2012 American Heart Association, Inc.

References

  1. 1.↵
    Heart Foundation. Cardiovascular Disease Statistics. Melbourne, Victoria, Australia: Heart Foundation; 2010.
  2. 2.↵
    Australian Institute of Health and Welfare. Cardiovascular Disease: Australian Facts 2011. Cardiovascular Disease Series. Canberra, ACT, Australia: Australian Institute of Health and Welfare; 2011.
  3. 3.↵
    1. Wiinberg N,
    2. Hoegholm A,
    3. Christensen HR,
    4. Bang LE,
    5. Mikkelsen KL,
    6. Nielsen PE,
    7. Svendsen TL,
    8. Kampmann JP,
    9. Madsen NH,
    10. Bentzon MW
    . 24-H ambulatory blood pressure in 352 normal Danish subjects, related to age and gender. Am J Hypertens. 1995;8:978–986.
    OpenUrlCrossRefPubMed
  4. 4.↵
    1. Arain FA,
    2. Kuniyoshi FH,
    3. Abdalrhim AD,
    4. Miller VM
    . Sex/gender medicine: the biological basis for personalized care in cardiovascular medicine. Circ J. 2009;73:1774–1782.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Becker RC,
    2. Terrin M,
    3. Ross R,
    4. Knatterud GL,
    5. Desvigne-Nickens P,
    6. Gore JM,
    7. Braunwald E
    . Comparison of clinical outcomes for women and men after acute myocardial infarction: the Thrombolysis in Myocardial Infarction Investigators. Ann Intern Med. 1994;120:638–645.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Blauwet LA,
    2. Redberg RF
    . The role of sex-specific results reporting in cardiovascular disease. Cardiol Rev. 2007;15:275–278.
    OpenUrlCrossRefPubMed
  7. 7.↵
    1. Kannel WB,
    2. Sorlie P,
    3. McNamara PM
    . Prognosis after initial myocardial infarction: the Framingham Study. Am J Cardiol. 1979;44:53–59.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. King KM,
    2. Ghali WA,
    3. Faris PD,
    4. Curtis MJ,
    5. Galbraith PD,
    6. Graham MM,
    7. Knudtson ML
    . Sex differences in outcomes after cardiac catheterization: effect modification by treatment strategy and time. JAMA. 2004;291:1220–1225.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Mallik S,
    2. Vaccarino V
    . Outcomes of thrombolytic therapy for acute myocardial infarction in women. Prog Cardiovasc Dis. 2004;47:58–71.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Shaw LJ,
    2. Bairey Merz CN,
    3. Pepine CJ,
    4. Reis SE,
    5. Bittner V,
    6. Kelsey SF,
    7. Olson M,
    8. Johnson BD,
    9. Mankad S,
    10. Sharaf BL,
    11. Rogers WJ,
    12. Wessel TR,
    13. Arant CB,
    14. Pohost GM,
    15. Lerman A,
    16. Quyyumi AA,
    17. Sopko G
    . Insights from the NHLBI-sponsored Women's Ischemia Syndrome Evaluation (WISE) Study: part I–gender differences in traditional and novel risk factors, symptom evaluation, and gender-optimized diagnostic strategies. J Am Coll Cardiol. 2006;47:S4–S20.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Vaccarino V,
    2. Parsons L,
    3. Every NR,
    4. Barron HV,
    5. Krumholz HM
    . Sex-based differences in early mortality after myocardial infarction: National Registry of Myocardial Infarction 2 participants. N Engl J Med. 1999;341:217–225.
    OpenUrlCrossRefPubMed
  12. 12.↵
    National Institutes of Health. Cardiovascular Disease in Women Module 1: Epidemiology. The Heart Truth. Bethesda, MD: National Institutes of Health; 2007.
  13. 13.↵
    1. Falconnet C,
    2. Bochud M,
    3. Bovet P,
    4. Maillard M,
    5. Burnier M
    . Gener difference in the response to an angiotensin-converting enzyme inhibitor and a diuretic in hypertensive patients of African descent. J Hypertens. 2004;22:1213–1220.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Hudson M,
    2. Rahme E,
    3. Behlouli H,
    4. Sheppard R,
    5. Pilote L
    . Sex differences in the effectiveness of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in patients with congestive heart failure: a population study. Eur J Heart Fail. 2007;9:602–609.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Miller JA,
    2. Cherney DZ,
    3. Duncan JA,
    4. Lai V,
    5. Burns KD,
    6. Kennedy CR,
    7. Zimpelmann J,
    8. Gao W,
    9. Cattran DC,
    10. Scholey JW
    . Gender differences in the renal response to renin-angiotensin system blockade. J Am Soc Nephrol. 2006;17:2554–2560.
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Zaparter P,
    2. Novalbos J,
    3. Gallego-Sandin S,
    4. Hernandez F,
    5. Abad-Santos F
    . Gender differences in angiotensin-converting enzyme (ACE) activity and inhibition by enalaprilat in healthy volunteers. J Cardiovasc Pharmacol. 2004;43:737–744.
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Charchar FJ,
    2. Tomaszewski M,
    3. Padmanabhan S,
    4. Lacka B,
    5. Upton MN,
    6. Inglis GC,
    7. Anderson NH,
    8. McConnachie A,
    9. Zukowska-Szczechowska E,
    10. Grzeszczak W,
    11. Connell JM,
    12. Watt GC,
    13. Dominiczak AF
    . The y chromosome effect on blood pressure in two European populations. Hypertension. 2002;39:353–356.
    OpenUrlAbstract/FREE Full Text
  18. 18.↵
    1. Ellis JA,
    2. Stebbing M,
    3. Harrap SB
    . Association of the human y chromosome with high blood pressure in the general population. Hypertension. 2000;36:731–733.
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Garcia EC,
    2. Gonzalez P,
    3. Castro MG,
    4. Alvarez R,
    5. Reguero JR,
    6. Batalla A,
    7. Cortina A,
    8. Alvarez V
    . Association between genetic variation in the y chromosome and hypertension in myocardial infarction patients. Am J Med Genet A. 2003;122A:234–237.
    OpenUrlPubMed
  20. 20.↵
    1. Uehara Y,
    2. Shin WS,
    3. Watanabe T,
    4. Osanai T,
    5. Miyazaki M,
    6. Kanase H,
    7. Taguchi R,
    8. Sugano K,
    9. Toyo-Oka T
    . A hypertensive father, but not hypertensive mother, determines blood pressure in normotensive male offspring through body mass index. J Hum Hypertens. 1998;12:441–445.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Dias DP,
    2. Oliveira M,
    3. Salgado HC,
    4. Fazan R Jr.
    . Ovariectomy does not affect the cardiac sympathovagal balance of female shr but estradiol does. Braz J Med Biol Res 2010;43:969–975.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Xing D,
    2. Nozell S,
    3. Chen YF,
    4. Hage F,
    5. Oparil S
    . Estrogen and mechanisms of vascular protection. Arterioscler Thromb Vasc Biol. 2009;29:289–295.
    OpenUrlAbstract/FREE Full Text
  23. 23.↵
    1. Yang XP,
    2. Reckelhoff JF
    . Estrogen, hormonal replacement therapy and cardiovascular disease. Curr Opin Nephrol Hypertens. 2011;20:133–138.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Chen YF,
    2. Meng QC
    . Sexual dimorphism of blood pressure in spontaneously hypertensive rats is androgen dependent. Life Sci. 1991;48:85–96.
    OpenUrlCrossRefPubMed
  25. 25.↵
    1. Crofton JT,
    2. Ota M,
    3. Share L
    . Role of vasopressin, the renin-angiotensin system and sex in dahl salt-sensitive hypertension. J Hypertens. 1993;11:1031–1038.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Ganten U,
    2. Schroder G,
    3. Witt M,
    4. Zimmermann F,
    5. Ganten D,
    6. Stock G
    . Sexual dimorphism of blood pressure in spontaneously hypertensive rats: effects of anti-androgen treatment. J Hypertens. 1989;7:721–726.
    OpenUrlPubMed
  27. 27.↵
    1. Iams SG,
    2. Wexler BC
    . Retardation in the development of spontaneous hypertension in sh rats by gonadectomy. J Lab Clin Med. 1977;90:997–1003.
    OpenUrlPubMed
  28. 28.↵
    1. Malyusz M,
    2. Ehrens HJ,
    3. Wrigge P
    . Effect of castration on the experimental renal hypertension of the rat: blood pressure, nephrosclerosis, long-chain fatty acids, and n-acetylation of PAH in the kidney. Nephron. 1985;40:96–99.
    OpenUrlPubMed
  29. 29.↵
    1. Masubuchi Y,
    2. Kumai T,
    3. Uematsu A,
    4. Komoriyama K,
    5. Hirai M
    . Gonadectomy-induced reduction of blood pressure in adult spontaneously hypertensive rats. Acta Endocrinol (Copenh). 1982;101:154–160.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Reckelhoff JF,
    2. Zhang H,
    3. Granger JP
    . Testosterone exacerbates hypertension and reduces pressure-natriuresis in male spontaneously hypertensive rats. Hypertension. 1998;31:435–439.
    OpenUrlAbstract/FREE Full Text
  31. 31.↵
    1. Rowland NE,
    2. Fregly MJ
    . Role of gonadal hormones in hypertension in the dahl salt-sensitive rat. Clin Exp Hypertens A. 1992;14:367–375.
    OpenUrlPubMed
  32. 32.↵
    1. Kumai T,
    2. Tanaka M,
    3. Watanabe M,
    4. Kobayashi S
    . Elevated tyrosine hydroxylase mrna levels in the adrenal medulla of spontaneously hypertensive rats. Jpn J Pharmacol. 1994;65:367–369.
    OpenUrlPubMed
  33. 33.↵
    1. Kumai T,
    2. Tanaka M,
    3. Watanabe M,
    4. Nakura H,
    5. Kobayashi S
    . Influence of androgen on tyrosine hydroxylase MRNA in adrenal medulla of spontaneously hypertensive rats. Hypertension. 1995;26:208–212.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Chen YF,
    2. Naftilan AJ,
    3. Oparil S
    . Androgen-dependent angiotensinogen and renin messenger rna expression in hypertensive rats. Hypertension. 1992;19:456–463.
    OpenUrlAbstract/FREE Full Text
  35. 35.↵
    1. Ellison KE,
    2. Ingelfinger JR,
    3. Pivor M,
    4. Dzau VJ
    . Androgen regulation of rat renal angiotensinogen messenger rna expression. J Clin Invest. 1989;83:1941–1945.
    OpenUrlCrossRefPubMed
  36. 36.↵
    1. Johnston CI,
    2. Fabris B,
    3. Jandeleit K
    . Intrarenal renin-angiotensin system in renal physiology and pathophysiology. Kidney Int. 1993;42(suppl):S59–S63.
    OpenUrl
  37. 37.↵
    1. Katz FH,
    2. Roper EF
    . Testosterone effect on renin system in rats. Proc Soc Exp Biol Med. 1977;155:330–333.
    OpenUrlAbstract/FREE Full Text
  38. 38.↵
    1. Zukowska-Grojec Z
    . Neuropeptide Y: a novel sympathetic stress hormone and more. Ann N Y Acad Sci. 1995;771:219–233.
    OpenUrlPubMed
  39. 39.↵
    1. Deenadayalu VP,
    2. White RE,
    3. Stallone JN,
    4. Gao X,
    5. Garcia AJ
    . Testosterone relaxes coronary arteries by opening the large-conductance, calcium-activated potassium channel. Am J Physiol Heart Circ Physiol. 2001;281:H1720–H1727.
    OpenUrlAbstract/FREE Full Text
  40. 40.↵
    1. Brown CJ,
    2. Goss SJ,
    3. Lubahn DB,
    4. Joseph DR,
    5. Wilson EM,
    6. French FS,
    7. Willard HF
    . Androgen receptor locus on the human X chromosome: regional localization to xq11–12 and description of a DNA polymorphism. Am J Hum Genet. 1989;44:264–269.
    OpenUrlPubMed
  41. 41.↵
    1. Yue P,
    2. Chatterjee K,
    3. Beale C,
    4. Poole-Wilson PA,
    5. Collins P
    . Testosterone relaxes rabbit coronary arteries and aorta. Circulation. 1995;91:1154–1160.
    OpenUrlAbstract/FREE Full Text
  42. 42.↵
    1. Isidori AM,
    2. Giannetta E,
    3. Greco EA,
    4. Gianfrilli D,
    5. Bonifacio V,
    6. Isidori A,
    7. Lenzi A,
    8. Fabbri A
    . Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf). 2005;63:280–293.
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Fu L,
    2. Gao QP,
    3. Shen JX
    . Relationship between testosterone and indexes indicating endothelial function in male coronary heart disease patients. Asian J Androl. 2008;10:214–218.
    OpenUrlCrossRefPubMed
  44. 44.↵
    1. Rettig R,
    2. Folberth CG,
    3. Stauss H,
    4. Kopf D,
    5. Waldherr R,
    6. Baldauf G,
    7. Unger T
    . Hypertension in rats induced by renal grafts from renovascular hypertensive donors. Hypertension. 1990;15:429–435.
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Harrap SB,
    2. Wang BZ,
    3. MacLellan DG
    . Renal transplantation between male and female spontaneously hypertensive rats. Hypertension. 1992;19:431–434.
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Reckelhoff JF,
    2. Zhang H,
    3. Srivastava K,
    4. Granger JP
    . Gender differences in hypertension in spontaneously hypertensive rats: role of androgens and androgen receptor. Hypertension. 1999;34:920–923.
    OpenUrlAbstract/FREE Full Text
  47. 47.↵
    1. James GD,
    2. Sealey JE,
    3. Muller F,
    4. Alderman M,
    5. Madhavan S,
    6. Laragh JH
    . Renin relationship to sex, race and age in a normotensive population. J Hypertens. 1986;4(suppl):S387–S389.
    OpenUrlCrossRef
  48. 48.↵
    1. Hall JE,
    2. Mizelle HL,
    3. Hildebrandt DA,
    4. Brands MW
    . Abnormal pressure natriuresis: a cause or a consequence of hypertension? Hypertension. 1990;15:547–559.
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Reckelhoff JF
    . Gender differences in the regulation of blood pressure. Hypertension. 2001;37:1199–1208.
    OpenUrlAbstract/FREE Full Text
  50. 50.↵
    1. Quinkler M,
    2. Bujalska IJ,
    3. Kaur K,
    4. Onyimba CU,
    5. Buhner S,
    6. Allolio B,
    7. Hughes SV,
    8. Hewison M,
    9. Stewart PM
    . Androgen receptor-mediated regulation of the α-subunit of the epithelial sodium channel in human kidney. Hypertension. 2005;46:787–798.
    OpenUrlAbstract/FREE Full Text
  51. 51.↵
    1. Lifton RP,
    2. Gharavi AG,
    3. Geller DS
    . Molecular mechanisms of human hypertension. Cell. 2001;104:545–556.
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Ely DL,
    2. Turner ME
    . Hypertension in the spontaneously hypertensive rat is linked to the y chromosome. Hypertension. 1990;16:277–281.
    OpenUrlAbstract/FREE Full Text
  53. 53.↵
    1. Negrin CD,
    2. McBride MW,
    3. Carswell HV,
    4. Graham D,
    5. Carr FJ,
    6. Clark JS,
    7. Jeffs B,
    8. Anderson NH,
    9. Macrae IM,
    10. Dominiczak AF
    . Reciprocal consomic strains to evaluate y chromosome effects. Hypertension. 2001;37:391–397.
    OpenUrlAbstract/FREE Full Text
  54. 54.↵
    1. Skaletsky H,
    2. Kuroda-Kawaguchi T,
    3. Minx PJ,
    4. Cordum HS,
    5. Hillier L,
    6. Brown LG,
    7. Repping S,
    8. Pyntikova T,
    9. Ali J,
    10. Bieri T,
    11. Chinwalla A,
    12. Delehaunty A,
    13. Delehaunty K,
    14. Du H,
    15. Fewell G,
    16. Fulton L,
    17. Fulton R,
    18. Graves T,
    19. Hou SF,
    20. Latrielle P,
    21. Leonard S,
    22. Mardis E,
    23. Maupin R,
    24. McPherson J,
    25. Miner T,
    26. Nash W,
    27. Nguyen C,
    28. Ozersky P,
    29. Pepin K,
    30. Rock S,
    31. Rohlfing T,
    32. Scott K,
    33. Schultz B,
    34. Strong C,
    35. Tin-Wollam A,
    36. Yang SP,
    37. Waterston RH,
    38. Wilson RK,
    39. Rozen S,
    40. Page DC
    . The male-specific region of the human y chromosome is a mosaic of discrete sequence classes. Nature. 2003;423:825–837.
    OpenUrlCrossRefPubMed
  55. 55.↵
    1. Hanley NA,
    2. Hagan DM,
    3. Clement-Jones M,
    4. Ball SG,
    5. Strachan T,
    6. Salas-Cortes L,
    7. McElreavey K,
    8. Lindsay S,
    9. Robson S,
    10. Bullen P,
    11. Ostrer H,
    12. Wilson DI
    . Sry, sox9, and dax1 expression patterns during human sex determination and gonadal development. Mech Dev. 2000;91:403–407.
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Parker KL,
    2. Schimmer BP
    . Genes essential for early events in gonadal development. Ann Med. 2002;34:171–178.
    OpenUrlPubMed
  57. 57.↵
    1. Wilhelm D,
    2. Palmer S,
    3. Koopman P
    . Sex determination and gonadal development in mammals. Physiol Rev. 2007;87:1–28.
    OpenUrlAbstract/FREE Full Text
  58. 58.↵
    1. Blagosklonova O,
    2. Fellmann F,
    3. Clavequin MC,
    4. Roux C,
    5. Bresson JL
    . Azfa deletions in sertoli cell-only syndrome: a retrospective study. Mol Hum Reprod. 2000;6:795–799.
    OpenUrlAbstract/FREE Full Text
  59. 59.↵
    1. Sun C,
    2. Skaletsky H,
    3. Birren B,
    4. Devon K,
    5. Tang Z,
    6. Silber S,
    7. Oates R,
    8. Page DC
    . An azoospermic man with a de novo point mutation in the y-chromosomal gene usp9y. Nat Genet. 1999;23:429–432.
    OpenUrlCrossRefPubMed
  60. 60.↵
    1. De Vries GJ,
    2. Rissman EF,
    3. Simerly RB,
    4. Yang LY,
    5. Scordalakes EM,
    6. Auger CJ,
    7. Swain A,
    8. Lovell-Badge R,
    9. Burgoyne PS,
    10. Arnold AP
    . A model system for study of sex chromosome effects on sexually dimorphic neural and behavioral traits. J Neurosci. 2002;22:9005–9014.
    OpenUrlAbstract/FREE Full Text
  61. 61.↵
    1. Jost A
    . The age factor in the castration of male rabbit fetuses. Proc Soc Exp Biol Med. 1947;66:302.
  62. 62.↵
    1. Berta P,
    2. Hawkins JR,
    3. Sinclair AH,
    4. Taylor A,
    5. Griffiths BL,
    6. Goodfellow PN,
    7. Fellous M
    . Genetic evidence equating sry and the testis-determining factor. Nature. 1990;348:448–450.
    OpenUrlCrossRefPubMed
  63. 63.↵
    1. Sinclair AH,
    2. Berta P,
    3. Palmer MS,
    4. Hawkins JR,
    5. Griffiths BL,
    6. Smith MJ,
    7. Foster JW,
    8. Frischauf AM,
    9. Lovell-Badge R,
    10. Goodfellow PN
    . A gene from the human sex-determining region encodes a protein with homology to a conserved DNA-binding motif. Nature. 1990;346:240–244.
    OpenUrlCrossRefPubMed
  64. 64.↵
    1. Arnold AP,
    2. Chen X
    . What does the “four core genotypes” mouse model tell us about sex differences in the brain and other tissues? Front Neuroendocrinol. 2009;30:1–9.
    OpenUrlCrossRefPubMed
  65. 65.↵
    1. Ji H,
    2. Zheng W,
    3. Wu X,
    4. Liu J,
    5. Ecelbarger CM,
    6. Watkins R,
    7. Arnold AP,
    8. Sandberg K
    . Sex chromosome effects unmasked in angiotensin ii-induced hypertension. Hypertension. 2010;55:1275–1282.
    OpenUrlAbstract/FREE Full Text
  66. 66.↵
    1. Turner ME,
    2. Farkas J,
    3. Dunmire J,
    4. Ely D,
    5. Milsted A
    . Which sry locus is the hypertensive y chromosome locus? Hypertension. 2009;53:430–435.
    OpenUrlAbstract/FREE Full Text
  67. 67.↵
    1. Ebrahimian T,
    2. He Y,
    3. Schiffrin EL,
    4. Touyz RM
    . Differential regulation of thioredoxin and NAD(P)H oxidase by angiotensin II in male and female mice. J Hypertens. 2007;25:1263–1271.
    OpenUrlCrossRefPubMed
  68. 68.↵
    1. Miller JA,
    2. Anacta LA,
    3. Cattran DC
    . Impact of gender on the renal response to angiotensin II. Kidney Int. 1999;55:278–285.
    OpenUrlCrossRefPubMed
  69. 69.↵
    1. Sampson AK,
    2. Moritz KM,
    3. Jones ES,
    4. Flower RL,
    5. Widdop RE,
    6. Denton KM
    . Enhanced angiotensin II type 2 receptor mechanisms mediate decreases in arterial pressure attributable to chronic low-dose angiotensin II in female rats. Hypertension. 2008;52:666–671.
    OpenUrlAbstract/FREE Full Text
  70. 70.↵
    1. Tatchum-Talom R,
    2. Eyster KM,
    3. Martin DS
    . Sexual dimorphism in angiotensin II-induced hypertension and vascular alterations. Can J Physiol Pharmacol. 2005;83:413–422.
    OpenUrlCrossRefPubMed
  71. 71.↵
    1. Xue B,
    2. Pamidimukkala J,
    3. Hay M
    . Sex differences in the development of angiotensin II-induced hypertension in conscious mice. Am J Physiol Heart Circ Physiol. 2005;288:H2177–H2184.
    OpenUrlAbstract/FREE Full Text
  72. 72.↵
    1. Xue B,
    2. Pamidimukkala J,
    3. Lubahn DB,
    4. Hay M
    . Estrogen receptor-α mediates estrogen protection from angiotensin II-induced hypertension in conscious female mice. Am J Physiol Heart Circ Physiol. 2007;292:H1770–H1776.
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    1. Ely D,
    2. Boehme S,
    3. Dunphy G,
    4. Hart M,
    5. Chiarappa F,
    6. Miller B,
    7. Martins AS,
    8. Turner M,
    9. Milsted A
    . The sry3 y chromosome locus elevates blood pressure and renin-angiotensin system indexes. Gend Med. 2011;8:126–138.
    OpenUrlCrossRefPubMed
  74. 74.↵
    1. Ishikawa I,
    2. Maeda K,
    3. Nakai S,
    4. Kawaguchi Y
    . Gender difference in the mean age at the induction of hemodialysis in patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis. 2000;35:1072–1075.
    OpenUrlPubMed
  75. 75.↵
    1. Neugarten J,
    2. Acharya A,
    3. Silbiger SR
    . Effect of gender on the progression of nondiabetic renal disease: a meta-analysis. J Am Soc Nephrol. 2000;11:319–329.
    OpenUrlAbstract/FREE Full Text
  76. 76.↵
    1. Seliger SL,
    2. Davis C,
    3. Stehman-Breen C
    . Gender and the progression of renal disease. Curr Opin Nephrol Hypertens. 2001;10:219–225.
    OpenUrlPubMed
  77. 77.↵
    1. Cao Z,
    2. Kelly DJ,
    3. Cox A,
    4. Casley D,
    5. Forbes JM,
    6. Martinello P,
    7. Dean R,
    8. Gilbert RE,
    9. Cooper ME
    . Angiotensin type 2 receptor is expressed in the adult rat kidney and promotes cellular proliferation and apoptosis. Kidney Int. 2000;58:2437–2451.
    OpenUrlCrossRefPubMed
  78. 78.↵
    1. Lahr G,
    2. Maxson SC,
    3. Mayer A,
    4. Just W,
    5. Pilgrim C,
    6. Reisert I
    . Transcription of the y chromosomal gene, sry, in adult mouse brain. Brain Res Mol Brain Res. 1995;33:179–182.
    OpenUrlCrossRefPubMed
  79. 79.↵
    1. Zwingman T,
    2. Fujimoto H,
    3. Lai LW,
    4. Boyer T,
    5. Ao A,
    6. Stalvey JR,
    7. Blecher SR,
    8. Erickson RP
    . Transcription of circular and noncircular forms of sry in mouse testes. Mol Reprod Dev. 1994;37:370–381.
    OpenUrlCrossRefPubMed
  80. 80.↵
    1. Ely D,
    2. Milsted A,
    3. Dunphy G,
    4. Boehme S,
    5. Dunmire J,
    6. Hart M,
    7. Toot J,
    8. Turner M
    . Delivery of sry1, but not sry2, to the kidney increases blood pressure and SNS indices in normotensive WKY rats. BMC Physiol. 2009;9:10.
  81. 81.↵
    1. Milsted A,
    2. Serova L,
    3. Sabban EL,
    4. Dunphy G,
    5. Turner ME,
    6. Ely DL
    . Regulation of tyrosine hydroxylase gene transcription by sry. Neurosci Lett. 2004;369:203–207.
    OpenUrlCrossRefPubMed
  82. 82.↵
    1. DiBona GF
    . The sympathetic nervous system and hypertension: recent developments. Hypertension. 2004;43:147–150.
    OpenUrlFREE Full Text
  83. 83.↵
    1. DiBona GF,
    2. Kopp UC
    . Neural control of renal function. Physiol Rev. 1997;77:75–197.
    OpenUrlAbstract/FREE Full Text
  84. 84.↵
    1. Esler M,
    2. Jennings G,
    3. Biviano B,
    4. Lambert G,
    5. Hasking G
    . Mechanism of elevated plasma noradrenaline in the course of essential hypertension. J Cardiovasc Pharmacol. 1986;8(suppl 5):S39–S43.
    OpenUrl
  85. 85.↵
    1. Kassab S,
    2. Kato T,
    3. Wilkins FC,
    4. Chen R,
    5. Hall JE,
    6. Granger JP
    . Renal denervation attenuates the sodium retention and hypertension associated with obesity. Hypertension. 1995;25:893–897.
    OpenUrlAbstract/FREE Full Text
  86. 86.↵
    1. Wyss JM,
    2. Oparil S,
    3. Sripairojthikoon W
    . Neuronal control of the kidney: contribution to hypertension. Can J Physiol Pharmacol. 1992;70:759–770.
    OpenUrlPubMed
  87. 87.↵
    1. Krum H,
    2. Schlaich M,
    3. Whitbourn R,
    4. Sobotka PA,
    5. Sadowski J,
    6. Bartus K,
    7. Kapelak B,
    8. Walton A,
    9. Sievert H,
    10. Thambar S,
    11. Abraham WT,
    12. Esler M
    . Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet. 2009;373:1275–1281.
    OpenUrlCrossRefPubMed
  88. 88.↵
    1. Schlaich MP,
    2. Sobotka PA,
    3. Krum H,
    4. Lambert E,
    5. Esler MD
    . Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med. 2009;361:932–934.
    OpenUrlCrossRefPubMed
  89. 89.↵
    1. Milsted A,
    2. Underwood AC,
    3. Dunmire J,
    4. DelPuerto HL,
    5. Martins AS,
    6. Ely DL,
    7. Turner ME
    . Regulation of multiple renin-angiotensin system genes by sry. J Hypertens. 2010;28:59–64.
    OpenUrlCrossRefPubMed
  90. 90.↵
    1. Miyakawa AA,
    2. de Lourdes Junqueira M,
    3. Krieger JE
    . Identification of two novel shear stress responsive elements in rat angiotensin I converting enzyme promoter. Physiol Genomics. 2004;17:107–113.
    OpenUrlAbstract/FREE Full Text
  91. 91.↵
    1. Xavier-Neto J,
    2. Pereira AC,
    3. Oliveira EM,
    4. Miyakawa AA,
    5. Junqueira ML,
    6. Krieger JE
    . Control of the rat angiotensin I converting enzyme gene by CRE-like sequences. Braz J Med Biol Res. 2004;37:1441–1453.
    OpenUrlCrossRefPubMed
  92. 92.↵
    1. Sartori-Valinotti JC,
    2. Iliescu R,
    3. Yanes LL,
    4. Dorsett-Martin W,
    5. Reckelhoff JF
    . Sex differences in the pressor response to angiotensin II when the endogenous renin-angiotensin system is blocked. Hypertension. 2008;51:1170–1176.
    OpenUrlAbstract/FREE Full Text
  93. 93.↵
    1. Armando I,
    2. Jezova M,
    3. Juorio AV,
    4. Terron JA,
    5. Falcon-Neri A,
    6. Semino-Mora C,
    7. Imboden H,
    8. Saavedra JM
    . Estrogen upregulates renal angiotensin II at(2) receptors. Am J Physiol Renal Physiol. 2002;283:F934–F943.
    OpenUrlAbstract/FREE Full Text
  94. 94.↵
    1. Nickenig G,
    2. Baumer AT,
    3. Grohe C,
    4. Kahlert S,
    5. Strehlow K,
    6. Rosenkranz S,
    7. Stablein A,
    8. Beckers F,
    9. Smits JF,
    10. Daemen MJ,
    11. Vetter H,
    12. Bohm M
    . Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation. 1998;97:2197–2201.
    OpenUrlAbstract/FREE Full Text
  95. 95.↵
    1. Silva-Antonialli MM,
    2. Tostes RC,
    3. Fernandes L,
    4. Fior-Chadi DR,
    5. Akamine EH,
    6. Carvalho MH,
    7. Fortes ZB,
    8. Nigro D
    . A lower ratio of AT1/AT2 receptors of angiotensin II is found in female than in male spontaneously hypertensive rats. Cardiovasc Res. 2004;62:587–593.
    OpenUrlAbstract/FREE Full Text
  96. 96.↵
    1. Liu J,
    2. Ji H,
    3. Zheng W,
    4. Wu X,
    5. Zhu JJ,
    6. Arnold AP,
    7. Sandberg K
    . Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17β-oestradiol-dependent and sex chromosome-independent. Biol Sex Differ. 2010;1:6.
View Abstract
Back to top
Previous ArticleNext Article

This Issue

Hypertension
March 2012, Volume 59, Issue 3
  • Table of Contents
Previous ArticleNext Article

Jump to

  • Article
    • Introduction
    • Sources of Funding
    • Disclosures
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • eLetters

Article Tools

  • Print
  • Citation Tools
    Y Are Males So Difficult to Understand?
    Amanda K. Sampson, Garry L.R. Jennings and Jaye P.F. Chin-Dusting
    Hypertension. 2012;59:525-531, originally published February 15, 2012
    https://doi.org/10.1161/HYPERTENSIONAHA.111.187880

    Citation Manager Formats

    • BibTeX
    • Bookends
    • EasyBib
    • EndNote (tagged)
    • EndNote 8 (xml)
    • Medlars
    • Mendeley
    • Papers
    • RefWorks Tagged
    • Ref Manager
    • RIS
    • Zotero
  •  Download Powerpoint
  • Article Alerts
    Log in to Email Alerts with your email address.
  • Save to my folders

Share this Article

  • Email

    Thank you for your interest in spreading the word on Hypertension.

    NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

    Enter multiple addresses on separate lines or separate them with commas.
    Y Are Males So Difficult to Understand?
    (Your Name) has sent you a message from Hypertension
    (Your Name) thought you would like to see the Hypertension web site.
  • Share on Social Media
    Y Are Males So Difficult to Understand?
    Amanda K. Sampson, Garry L.R. Jennings and Jaye P.F. Chin-Dusting
    Hypertension. 2012;59:525-531, originally published February 15, 2012
    https://doi.org/10.1161/HYPERTENSIONAHA.111.187880
    del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Related Articles

Cited By...

Subjects

  • Genetics
    • Genetics
  • Basic, Translational, and Clinical Research
    • Animal Models of Human Disease

Hypertension

  • About Hypertension
  • Instructions for Authors
  • AHA CME
  • Guidelines and Statements
  • Permissions
  • Journal Policies
  • Email Alerts
  • Open Access Information
  • AHA Journals RSS
  • AHA Newsroom

Editorial Office Address:
7272 Greenville Ave.
Dallas, TX 75231
email: hypertension@heart.org

Information for:
  • Advertisers
  • Subscribers
  • Subscriber Help
  • Institutions / Librarians
  • Institutional Subscriptions FAQ
  • International Users
American Heart Association Learn and Live
National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service

  • 1-800-AHA-USA-1
  • 1-800-242-8721
  • Local Info
  • Contact Us

About Us

Our mission is to build healthier lives, free of cardiovascular diseases and stroke. That single purpose drives all we do. The need for our work is beyond question. Find Out More about the American Heart Association

  • Careers
  • SHOP
  • Latest Heart and Stroke News
  • AHA/ASA Media Newsroom

Our Sites

  • American Heart Association
  • American Stroke Association
  • For Professionals
  • More Sites

Take Action

  • Advocate
  • Donate
  • Planned Giving
  • Volunteer

Online Communities

  • AFib Support
  • Garden Community
  • Patient Support Network
  • Professional Online Network

Follow Us:

  • Follow Circulation on Twitter
  • Visit Circulation on Facebook
  • Follow Circulation on Google Plus
  • Follow Circulation on Instagram
  • Follow Circulation on Pinterest
  • Follow Circulation on YouTube
  • Rss Feeds
  • Privacy Policy
  • Copyright
  • Ethics Policy
  • Conflict of Interest Policy
  • Linking Policy
  • Diversity
  • Careers

©2018 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is a qualified 501(c)(3) tax-exempt organization.
*Red Dress™ DHHS, Go Red™ AHA; National Wear Red Day ® is a registered trademark.

  • PUTTING PATIENTS FIRST National Health Council Standards of Excellence Certification Program
  • BBB Accredited Charity
  • Comodo Secured